[{"orgOrder":0,"company":"Praetego","sponsor":"National Eye Institute","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"PTG-630","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Praetego","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Praetego \/ National Eye Institute","highestDevelopmentStatusID":"4","companyTruncated":"Praetego \/ National Eye Institute"}]

Find Clinical Drug Pipeline Developments & Deals by Praetego

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Praetego's NEI grant expands PTG-630 to a third indication and builds upon promising findings in both Alzheimer's disease and diabetic peripheral neuropathy. PTG-630 has demonstrated remarkable potency as an AGE inhibitor.

                          Brand Name : PTG-630

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          March 01, 2023

                          Lead Product(s) : PTG-630

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : National Eye Institute

                          Deal Size : $0.3 million

                          Deal Type : Funding

                          blank